# eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Source: https://onco.cc/trials/nct02767804/  
OnCo record `nct02767804` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ensartinib, Crizotinib in non-small-cell lung cancer and small-cell lung cancer, run by Xcovery Holdings, Inc., active and no longer recruiting.

## Summary

eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients is a phase 3 interventional study registered as NCT02767804 by Xcovery Holdings, Inc., with 290 participants enrolled, started 2016-06 and due to reach its primary completion in 2025-12-30. Interventions recorded: X-396 (ensartinib), crizotinib. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT02767804
- Phase: 3
- Setting: Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
- Sponsor: Xcovery Holdings, Inc.
- Enrolled: 290

## Sources

- ClinicalTrials.gov NCT02767804: https://clinicaltrials.gov/study/NCT02767804

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Crizotinib](https://onco.cc/drugs/crizotinib/), [Ensartinib](https://onco.cc/drugs/ensartinib/)
- companies: [Xcovery](https://onco.cc/companies/xcovery/)

---
JSON: https://onco.cc/api/v1/entities/nct02767804.json